David Reddy is Director General of IFPMA, leading the organization’s mission to translate scientific progress into the next generation of medicines and vaccines and championing innovation that delivers a healthier future for people everywhere.  

Prior to joining IFPMA, David  served for 13 years as CEO of Medicines for Malaria Venture (MMV), where he played a pivotal role as the organization established the largest portfolio of malaria drugs ever assembled, bringing forward 15 medicines that have saved more than 15 million lives.

In 2026, David joined the World Health Summit Council.  He has also been a Board Member of the Coalition for Epidemic Preparedness (CEPI) from 2018-2026 and serves on the Board of Malaria No More UK.

Before joining MMV, David was a Vice President at Roche, where he held corporate responsibility for Roche’s response to the 2009/2010 influenza pandemic. In this role, he led the work to develop, communicate, and implement the company’s strategy for working with governments and the WHO on pandemic preparedness, and establishing a sustainable access program. Prior to this, he led Roche’s HIV/AIDS Disease Area Strategy Team, providing strategic leadership for Roche’s HIV portfolio.

David holds a PhD in Cellular and Molecular Biology from the University of Auckland, New Zealand and completed a post-doctoral fellowship in molecular neurobiology at the Friedrich-Miescher Institute in Basel, Switzerland. David has more than 30 years of management experience in the healthcare sector, including leadership of drug development teams including working on anti-viral diagnostics, a recombinant vaccine, and novel antiviral strategies; licensing and alliance management; market analytics and business planning; product and disease area management; and interfacing with governments, NGOs, and patient advocacy groups in priority disease areas.